Diabetes

Zhittya Genesis Medicine is exploring the transformative potential of Fibroblast Growth Factor 1 (FGF-1) as a treatment for diabetes, targeting vascular dysfunction and impaired glucose regulation at the root of the disease. Research from leading institutions like the Salk Institute and the Howard Hughes Medical Institute has highlighted FGF-1’s ability to regulate blood glucose levels independently of insulin by inhibiting fat breakdown, offering hope for patients with insulin resistance. Additionally, FGF-1’s angiogenic properties stimulate the growth of new blood vessels, addressing complications such as peripheral artery disease and diabetic foot ulcers. By enhancing blood flow, promoting wound healing, and potentially restoring vascular and metabolic health, FGF-1 represents a groundbreaking approach to mitigating the long-term effects of diabetes and improving the lives of millions worldwide.